Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes-Reference-Cited by-同舟云学术

Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes

Published:2018-08 Issue:8 Volume:11 Page:
ISSN:2574-8300
Container-title:Circulation: Genomic and Precision Medicine
language:en
Short-container-title:Circ Genom Precis Med.

Author:

Parikh Kishan S.¹²,Fiuzat Mona¹,Davis Gordon³,Neely Megan¹,Blain-Nelson Penny⁴,Whellan David J.⁵,Abraham William T.⁶,Adams Kirkwood F.⁷,Felker G. Michael¹²,Liggett Stephen B.⁸,O’Connor Christopher M.¹⁹,Bristow Michael R.³⁴

Affiliation:

1. Duke Clinical Research Institute (K.S.P., M.F., M.N., M.F., G.M.F., C.M.O.).

2. Department of Medicine, Duke University School of Medicine, Durham, NC (K.S.P., G.M.F.).

3. ARCA Biopharma, Westminster, CO (G.D., M.R.B.).

4. Department of Medicine, University of Colorado, Aurora (P.B.-N., M.R.B.).

5. Sidney Kimmel Medical College, Philadelphia, PA (D.J.W.).

6. Department of Medicine, Ohio State University, Columbus (W.T.A.).

7. Department of Medicine, University of North Carolina at Chapel Hill (K.F.A.).

8. Department of Medicine, University of South Florida Morsani College of Medicine, Tampa (S.B.L.).

9. Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference20 articles.

1. A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure

2. Combinatorial Pharmacogenetic Interactions of Bucindolol and β1, α2C Adrenergic Receptor Polymorphisms

3. A polymorphism within a conserved beta1-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure

4. Potential Applications of Pharmacogenomics to Heart Failure Therapies

5. β1 Adrenergic Receptor Polymorphisms and Heart Failure: A Meta-Analysis on Susceptibility, Response to β-Blocker Therapy and Prognosis

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta‐Blocker Therapy;Clinical Pharmacology & Therapeutics;2024-07

2. Adrenoceptor Desensitization: Current Understanding of Mechanisms;Pharmacological Reviews;2024-01-30

3. Chimeric cohorts and consortia can power and scale precision medicine;Comprehensive Precision Medicine;2024

4. Non‑synonymous polymorphisms in the HRC and ADRB1 genes may be associated with all‑cause death in patients with non‑ischemic heart failure;Experimental and Therapeutic Medicine;2023-12-04

5. β1-adrenergic receptor polymorphisms: a possible genetic predictor of bisoprolol response in acute coronary syndrome;Future Science OA;2023-12